Align Technology (ALGN)
(Delayed Data from NSDQ)
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$212.15 USD
+1.37 (0.65%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum C VGM
Zacks News
Wright Medical Group (WMGI) Q2 Loss Narrower than Expected
by Zacks Equity Research
Wright Medical Group N.V. (WMGI) posted narrower-than-expected loss on account of strong growth in the U.S.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Inogen (INGN) delivers better-than-expected results in Q2 with significant contributions from the Business-to-Business segment. Moreover, raised guidance buoys optimism.
Illumina (ILMN) Rides on New Products, Low Margin a Concern
by Zacks Equity Research
Illumina (ILMN) continues to grow in high-potential genetic research market through innovation and product launches.
Bruker (BRKR) Q2 Earnings & Revenues Beat Estimates, View Up
by Zacks Equity Research
Bruker (BRKR) delivers a better-than-expected Q2, largely driven by strength in CALID Group and BEST. Moreover, a raised guidance buoys optimism.
Bull of the Day: Align Technology (ALGN)
by Kevin Cook
The clear winner in alternative dental alignment continues to make long-term investors smile
Hologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance
by Zacks Equity Research
Hologic's (HOLX) revenue growth in molecular diagnostics and GYN Surgical offset by poor blood screening and Breast Imaging show.
Cardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top
by Zacks Equity Research
Cardiovascular Systems' (CSII) lower operating expenses drove the year-over-year improvement in Q4 earnings.
Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2
by Zacks Equity Research
Genomic Health (GHDX) continues to lag expectations despite strong adoption of its Oncotype DX test.
Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View
by Zacks Equity Research
Illumina (ILMN) delivers an impressive Q2 on strong uptake of sequencing consumables and microarrays and continued adoption of NovaSeq platform. A raised guidance buoys optimism.
ResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track
by Zacks Equity Research
ResMed's Q4 results (RMD) register strong sales in sleep devices, respiratory care devices, mask systems and software solutions.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.
VWR Corp (VWR) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
VWR Corp (VWR) reported an impressive Q2 and is presently awaiting a merger with Avantor.
IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
Hill-Rom Holdings (HRC) Beats Q3 Earnings, Misses Revenues
by Zacks Equity Research
Hill-Rom Holdings (HRC) rides high on international growth and product innovation.
Company News For July 31, 2017
by Zacks Equity Research
Companies in the news are: EXPE,MRK,ALGN,MAT
NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View
by Zacks Equity Research
NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.
Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.
AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?
by Zacks Equity Research
AmerisourceBergen's (ABC) third-quarter performance face risks from reduced contract renewals and lower generic inflation.
Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Despite Abaxis' lackluster performance in the fiscal first quarter, its new marketing strategies and recent launches buoy optimism.
GNC Holdings (GNC) Tops Q2 Earnings, Misses Sales Estimates
by Zacks Equity Research
Sluggish performance by the U.S. & Canada international and manufacturing/wholesale segments marred second-quarter results for GNC Holdings (GNC).
Align Technology (ALGN) Beats on Q2 Earnings and Revenues
by Zacks Equity Research
Align Technology (ALGN) rides high in Q2 banking on robust growth in the Invisalign space.
QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View
by Zacks Equity Research
QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.
Merit Medical Systems (MMSI) Worth a Look: Stock Gains 7.7%
by Zacks Equity Research
Merit Medical Systems, Inc. (MMSI) shares rose almost 8% in the last trading session.
McKesson (MCK) Misses Earnings Estimates in Q1, Raises View
by Zacks Equity Research
McKesson's (MCK) performance was muted in the first quarter owing to branded to generic conversions and competition in its pharmacy business.
Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss
by Zacks Equity Research
Integra LifeSciences' (IART) solid performance in the Orthopedics and Tissue Technologies was the key highlight of the second quarter.